TRACK 2: From Bench to Bedside: Bioanalysis and Translational Science

(T0930-02-06) Co-culture of Pre-programmed Angiogenic and Osteogenic Gingival Stem Cells Enhances Osteogenesis

(T0930-02-07) Comparison of Various Methods to Quantitate mRNA from LNP-mRNA-ABC in Human Serum

(M0930-02-07) Low Blood Volume Alternative for Monitoring COVID-Specific T-Cell Immunity

(M0930-02-08) Fit for Purpose Qualified Assays to Assess Exploratory Biomarkers in Human Aqueous Humor to Unveil Target Engagement and Pharmacological Activity in Complement Factor C5 Inhibition Clinical Studies

(T0930-02-08) Validation of an Anti-Drug Antibody Assay Against an Oncolytic Virus Immunotherapeutic

(M0930-02-09) Comprehensive Pharmacokinetic Profiling of C004019: A PROTAC Targeting Tau Protein in Neurodegenerative Disorders

(T0930-02-09) Polyplex Particle Size Alters Transgene Expression and Cell Viability in a Cell Type-Dependent Manner

(T1030-02-06) Qualification of the S-PLEX Neurology Panel 1 (GFAP, NfL and Tau) MSD Assay

(M1030-02-06) The Importance of Pairing a Matrix with a Nucleic Acid Extraction Approach: Compilation of 66 Bioanalytical PCR (qPCR and dPCR) Validations

(M1030-02-07) Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies

(M1030-02-08) Simplifying Cellular Immunogenicity Monitoring for Novel Therapeutics through a sMHC-1 Immunopeptidomics Approach

(T1030-02-08) Systematic Optimization of ADA Assays for Complex Biologics: A Framework for Addressing Assay Challenges Across Modalities

(M1030-02-09) Advancing Peripheral Blood Mononuclear Cells Isolation for ELISPOT Analysis: Time Is Critical

(M1130-02-06) Anti-Urolithiatic and Diuretic Activities of Ethyl Acetate Fraction of Grewia flavescens Roots

(T1130-02-06) Using Tasso-M20 Microsampling Device to Support a Clinical PK Study

(M1130-02-07) Embracing Singlicate Ligand Binding Biomarker Assays: A Case Study Comparing Duplicate vs Singlicate Analysis for the Determination of IL-6, IFN-gamma, and TNF-alpha in Human Sodium Heparin Plasma

(T1130-02-07) Mitigation of the Presence of Crosstalk in an ADA Bridging Assay Using the MSD Platform for the Detection of Antibodies against an Antibody-Drug Conjugate

(M1130-02-08) Conserving Biorelevant Enzymatic Activity during In Vitro Analysis of Biotransformable Drugs

(T1130-02-08) Evaluation of the MSD S-Plex Neuropanel 1 Multiplex Assay for Neurological Biomarkers

(M1130-02-09) Alternative Detergents to Triton X-100 for Disrupting Lipid Nanoparticles and Enhancing RNA Encapsulation Quantification in RiboGreen Assay

(T1130-02-09) Considerations for Probe Selection for Oligonucleotide Hybridization LC/MS Workflows

(M1230-02-06) Application of icIEF-UV/MS for Rapid Proteoform Characterization and Charge Variant Analysis of a Novel Antibody-Drug Conjugate in Drug Discovery

(T1230-02-06) Fostering Innovation and Expanding Institutional Research from Bench to Bedside

(M1230-02-07) Development and Validation of a High-Sensitivity PK Assay for CLN-978 Supporting a First in Human Study in Systemic Lupus Erythematosus Using Quanterix SIMOA Technology

(T1230-02-07) Highly Specific Bridging ECL Assay for Small Peptide Drug Modalities and Their Use as an Alternative to a Direct ELISA Approach

(M1230-02-08) Comprehensive AAV-Based Vector Shedding Assessment by PCR:  A Case Study with Whole Blood, Serum, Semen, Urine, and Buccal Swab

(T1230-02-08) Reverse Translational Modeling for Early Benchmarking of Clinically Active Doses from In Vitro Cell Killing and T-Cell Activation Data for BCMAxCD3 T-Cell Engagers

(M1230-02-09) Bringing Unstable Flow Cytometry Assays Closer to the Patient: Case Study of an Ex Vivo CD11b Stimulation Flow Cytometry Assay Collected at External Clinical Site

(T1330-02-06) Enhancing Immunogenicity Risk Assessment: Leveraging ISPRI for Bispecific Antibody Analysis

(M1330-02-06) Establishing Cellular Mechanisms Underlying Species-Related Differences in the Effective Delivery of LNP-mRNA to Overcome Limitations of Human Dose Translation

(M1330-02-07) Investigating Off Target Pharmacology and Metabolism of Methapyrilene Using Metabolomics, Lipidomics, and MS Imaging: A Case Study

(T1330-02-07) Quantitative Bioanalysis of Large Peptides and Proteins: Case Study of GLP-1 Receptor Agonist Semaglutide in Plasma

(M1330-02-08) Analysis of Pre-existing Anti-AAV Antibodies Using a Novel Nanoliter Total Antibody Assay: A Serotype-Independent Approach

(T1330-02-08) First-in-Human Dose Optimization of Enavogliflozin Eye Drops via Population PBPK Modeling for Treatment of Diabetic Retinopathy

(T1330-02-09) Preliminary Phase 1a Clinical Results of Multispecific Antibody TAVO412 in Patients with Hard-to-Treat Solid Tumors

(M1330-02-09) Qualification of a Novel Multiplex Assay for the Quantitation of Chemokine Markers in Human Plasma and CSF Samples

(T1430-02-06) Immunogenicity Assessment of Both Anti-Drug Antibodies in Experimental Animals: Complexed with Drug or in Free Form Using an Automated Workflow

(T1430-02-07) Advancements in Free Heme Analysis: Utilizing a Co-Solvent to Simplify Sample Preparation

(M1430-02-07) Assessment of Antibody-Drug Conjugate Stability in Mouse Skin Homogenate Supernatant Using Liquid Chromatographic-Quadrupole Time-of-Flight Mass Spectrometric Method

(T1430-02-08) A Sensitive, Specific and High-throughput Assay to Quantify an Oligonucleotide Therapeutics in Monkey Liver using Stem‑Loop RT-qPCR Platform

(M1430-02-08) Structural Modifications of Phosphatidylserine and Their Impact on Oral Tolerance

(M1430-02-09) Application of Sequential Window Acquisition of all Theoretical Fragment Ion Spectra Mass Spectrometry (SWATH-MS) for Identification of Tetrapeptide Linker Cleavage Profile of Antibody Drug Conjugate

(T1430-02-09) Overcoming Selectivity Barriers of a Ligand Binding Assay

(M1530-02-06) Improving Drug Tolerance in Anti-Drug Antibody (ADA) Assay using PandA Method – Case Studies

(M1530-02-07) Simultaneous Analysis of Antibody-Conjugated Drug(acDrug) and Total Antibody(tAb) for Antibody Drug Conjugate Using Dual Enzyme-Assisted Sample Preparation Followed by LC-MS

(M1530-02-08) Charge Variant Profiling of Antibody-Drug Conjugate Containing Auristatins Using icIEF-UV-MS

(M1530-02-09) Development of a High Throughput LC-MS/MS 1.5 Plex Assay for Quantitation of Total Antibody (TAb) and Intact Antibody Drug Conjugate (ADC) Using Immunoprecipitation by Specific Receptor Capture

(M1430-02-06) Clinical Evidence of Safety, Prolonged Half-Life, and Low Immunogenicity of Monoclonal Antibodies TAVO101 and TAVO103 Engineered with Multiple Fc Mutations